Patients with renal cell cancer (RCC) develop metastatic spread in approximately 33% of cases. The clinical management of patients with metastatic RCC is complicated by the lack of significant efficacy from available therapies. Common sites of metastases include the lung, liver, bone, brain, and adrenal gland, with case reports detailing the capacity of RCC to appear almost anywhere in the body. More than one organ system is often involved in the metastatic process. Metastases may be found at diagnosis or at some interval after nephrectomy. Approximately 20% to 50% of patients will eventually develop metastatic disease after nephrectomy. A shorter interval between nephrectomy and the development of metastases is associated with a poorer prognosis. Patients with metastatic RCC face a dismal prognosis, with a median survival time of only 6 to 12 months and a 2-year survival rate of 10% to 20%. Recent advances in biologic response modifier therapy have brought new hope to a small percentage of patients who respond to this therapy and rekindled interest in cytoreductive nephrectomy as an integral part of the management of these patients.
KeywordsVascular Endothelial Growth Factor Renal Cell Carcinoma Renal Cell Cancer Metastatic Renal Cell Carcinoma Flavopiridol
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Chow W, Devesa S, Warren J, Fraumeri J: Rising incidence of renal cell cancer in the United States. JAMA 1999, 281:1628–1631. The rising incidence of RCC in the United States is provocative. Based on current data, this increase seems to be occurring in local and distant disease.PubMedCrossRefGoogle Scholar
- 8.Thrasher JB, Paulson DF: Prognostic factors in renal cancer. Urol Clin North Am 1993, 2:247–262.Google Scholar
- 11.Flanigan RC, Salmon SE, Blumenstein BA, et al.: Nephrectomy followed by interferon alfa-2b compared to interferon alfa-2b alone for metastatic renal cell cancer. N Engl J Med 2001, 345:1655–1659. This paper represents the first prospective randomized trial demonstrating the role of cytoreductive nephrectomy in metastatic RCC. The outcomes are stratified by pretreatment stratification variables.PubMedCrossRefGoogle Scholar
- 13.Zisman A, Pantuck AJ, Wieder J, et al.: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002, 20:4559–4566. Based on the extensive experience at UCLA (Los Angeles, CA) with RCC, the authors have developed a useful schema for the prediction of outcomes.PubMedCrossRefGoogle Scholar
- 30.Motzer RJ, Bacik J, Mariani T, et al.: Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear cell histology. J Clin Oncol 2002, 20:2376–2381. This interesting manuscript describes the behavior of nonclear cell RCC. This is valuable information in the era of increased appreciation of the various types of RCC and their individual characteristics.PubMedCrossRefGoogle Scholar
- 31.Mickisch GH, Garin A, van Poppel H, et al.: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal cell carcinoma. Lancet 2001, 358:966–970. This prospective randomized trial of cytoreductive nephrectomy was done by the European Organization for Research and Treatment of Cancer and uses the SWOG protocol . It provides additional useful support of the concept of cytoreductive nephrectomy.PubMedCrossRefGoogle Scholar
- 32.van Veldhuizen PJ, Faulkner JR, Lara PN, et al.: A phase II study of flavopiridol (Flavo) in patients with advanced renal cell cancer: results of Southwest Oncology Group trial S0109 [abstract]. Am Soc Clin Oncol 2003:1552a.Google Scholar
- 33.Childs R, Chernoff A, Contentin N, et al.: Regression of metastatic renal cell carcinoma after nonmyeloablative allogenic peripheral blood stem cell transplantation. N Engl J Med 2000, 343:750–758. Miniallotransplantation provides a new and interesting look at the biologic behavior of metastatic RCC and a useful technique for patients with this disease. The toxicity and early success of this concept is discussed.PubMedCrossRefGoogle Scholar